• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Correlation between free platinum AUC and total platinum measurement 24 h after i.v. bolus injection of cisplatin in humans.

作者信息

Fournier C, Vennin P, Hecquet B

机构信息

Laboratoire de Pharmacodynamie Clinique, Centre Oscar Lambret, Lille, France.

出版信息

Cancer Chemother Pharmacol. 1988;21(1):75-7. doi: 10.1007/BF00262745.

DOI:10.1007/BF00262745
PMID:3342469
Abstract

The plasma kinetics of platinum after i.v. bolus administration of cisplatin was determined for 17 patients with advanced cancer. Statistical analysis of individual values revealed a high correlation between the area under the plasma concentration-time curve (AUC) of free platinum (unbound to proteins) and the concentration of platinum bound to plasma proteins 24 h after drug administration (Cp24). A similar correlation was found between the peak plasma values of ultrafiltrable platinum (Cp0) and Cp24. When studied in the same patient, increases in free platinum AUC and Cp0 were also found to result in increased Cp24. It is suggested that a single measurement of plasma platinum concentration 24 h after i.v. infusion of cisplatin could be a simple method either of detecting patients with extreme values of AUC and Cp0 or of studying the evolution of these parameters during multiple courses of treatment, although it cannot be used to give precise values for AUC and Cp0.

摘要

相似文献

1
Correlation between free platinum AUC and total platinum measurement 24 h after i.v. bolus injection of cisplatin in humans.
Cancer Chemother Pharmacol. 1988;21(1):75-7. doi: 10.1007/BF00262745.
2
Kinetics of plasma platinum in a hemodialysis patient receiving repeated doses of cisplatin.接受重复剂量顺铂治疗的血液透析患者血浆铂的动力学
Oncol Rep. 2000 Nov-Dec;7(6):1243-5. doi: 10.3892/or.7.6.1243.
3
Continuous infusion of high-dose cisplatin in children: pharmacokinetics of free and total platinum.
Eur J Cancer Clin Oncol. 1987 Nov;23(11):1649-52. doi: 10.1016/0277-5379(87)90444-5.
4
Pharmacokinetics and tumor concentration of intraarterial and intravenous cisplatin in patients with head and neck squamous cancer.
Cancer Chemother Pharmacol. 1992;30(3):221-5. doi: 10.1007/BF00686317.
5
Evaluation of a prediction model of cisplatin dose based on total platinum plasma concentration.
Eur J Cancer. 1996 Sep;32A(10):1734-8. doi: 10.1016/0959-8049(96)00171-2.
6
Local distribution into brain tumor and pharmacokinetics of 4-pyridoxate diammine hydroxy platinum, a novel cisplatin derivative, after intracarotid administration in rats with 9L malignant glioma: simultaneous brain microdialysis study.新型顺铂衍生物4-吡啶酸二胺羟基铂经颈内动脉给药后在9L恶性胶质瘤大鼠脑肿瘤中的局部分布及药代动力学:同步脑微透析研究
Biol Pharm Bull. 2000 Dec;23(12):1491-6. doi: 10.1248/bpb.23.1491.
7
[Pharmacokinetics of plasma and cerebrospinal fluid cisplatin in patients with malignant glioma and metastatic brain tumor after selective intraarterial or intravenous and intracarotid administration of etoposide and cisplatin].[恶性胶质瘤和转移性脑肿瘤患者在选择性动脉内或静脉及颈动脉给予依托泊苷和顺铂后血浆和脑脊液中顺铂的药代动力学]
No Shinkei Geka. 1994 Jan;22(1):35-42.
8
[Intraperitoneal versus intravenous infusion of cis-platinum in advanced ovarian cancer--examination of pharmacokinetics].[晚期卵巢癌中顺铂腹腔内注射与静脉输注的药代动力学研究]
Gan To Kagaku Ryoho. 1987 Mar;14(3 Pt 1):639-44.
9
Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients.顺铂在儿科患者中的药代动力学及其与肾毒性的关系。
Eur J Clin Pharmacol. 2001 Aug;57(5):393-402. doi: 10.1007/s002280100319.
10
Cisplatin nephrotoxicity in children after continuous 72-h and 3x1-h infusions.
Pediatr Nephrol. 2001 Jul;16(7):586-93. doi: 10.1007/s004670100610.

引用本文的文献

1
Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer.卵巢癌腹腔化疗后顺铂和紫杉醇的全身暴露。
Cancer Chemother Pharmacol. 2023 Mar;91(3):247-256. doi: 10.1007/s00280-023-04512-z. Epub 2023 Mar 9.
2
Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.chk1/2 抑制克服了由于功能性 p53 丧失导致的头颈部癌细胞对顺铂的耐药性。
Mol Cancer Ther. 2013 Sep;12(9):1860-73. doi: 10.1158/1535-7163.MCT-13-0157. Epub 2013 Jul 9.
3
Pharmacokinetics of cisplatin during hyperthermic intraperitoneal treatment of peritoneal carcinomatosis.

本文引用的文献

1
Clinical kinetics on intact cisplatin and some related species.完整顺铂及一些相关物种的临床动力学。
Clin Pharmacol Ther. 1981 May;29(5):658-64. doi: 10.1038/clpt.1981.91.
2
Pharmacokinetics of free platinum species following rapid, 3-hr and 24-hr infusions of cis-diamminedichloroplatinum (II) and its therapeutic implications.顺二氨二氯铂(II)快速输注、3小时输注和24小时输注后游离铂物种的药代动力学及其治疗意义。
Eur J Cancer Clin Oncol. 1982 Nov;18(11):1069-74. doi: 10.1016/0277-5379(82)90085-2.
3
In vitro interactions of TNO6 with human plasma.
顺铂在腹腔热灌注治疗腹膜癌转移中的药代动力学。
Eur J Clin Pharmacol. 2013 Mar;69(3):533-40. doi: 10.1007/s00228-012-1405-4. Epub 2012 Sep 16.
4
A systematic review of limited sampling strategies for platinum agents used in cancer chemotherapy.癌症化疗中铂类药物有限采样策略的系统评价
Clin Pharmacokinet. 2007;46(6):471-94. doi: 10.2165/00003088-200746060-00002.
5
A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve.一种用于估算游离卡铂血浆浓度-时间曲线下面积的单样本分析方法。
Cancer Chemother Pharmacol. 1996;37(5):429-34. doi: 10.1007/s002800050408.
6
Pharmacokinetic and biotransformation studies of ormaplatin in conjunction with a phase I clinical trial.奥马铂的药代动力学和生物转化研究以及一项I期临床试验
Cancer Chemother Pharmacol. 1994;33(4):347-54. doi: 10.1007/BF00685911.
7
Long-term pharmacokinetic behavior of platinum after cisplatin administration.顺铂给药后铂的长期药代动力学行为。
Cancer Chemother Pharmacol. 1995;37(1-2):97-102. doi: 10.1007/BF00685635.
Cancer Chemother Pharmacol. 1983;11(3):177-81. doi: 10.1007/BF00254200.
4
Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity.血浆铂水平:与顺铂剂量及肾毒性的关系。
Cancer Treat Rep. 1983 Feb;67(2):169-72.
5
Cisplatin metabolites in plasma, a study of their pharmacokinetics and importance in the nephrotoxic and antitumour activity of cisplatin.血浆中的顺铂代谢产物:其药代动力学及在顺铂肾毒性和抗肿瘤活性中的重要性研究
Biochem Pharmacol. 1984 Oct 1;33(19):3063-70. doi: 10.1016/0006-2952(84)90610-5.
6
Clinical pharmacokinetics of commonly used anticancer drugs.常用抗癌药物的临床药代动力学
Clin Pharmacokinet. 1983 May-Jun;8(3):202-32. doi: 10.2165/00003088-198308030-00002.
7
Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion.
Cancer Chemother Pharmacol. 1980;5(1):21-6. doi: 10.1007/BF00578558.
8
Antitumor activity and toxicity of serum protein-bound platinum formed from cisplatin.
Jpn J Cancer Res. 1985 Jan;76(1):68-74.
9
Anticancer drug pharmacodynamics.抗癌药药效学
Cancer Chemother Pharmacol. 1985;14(3):177-83. doi: 10.1007/BF00258112.
10
Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry.用无火焰原子吸收分光光度法分析生物材料中的铂。
Biochem Med. 1977 Oct;18(2):184-91. doi: 10.1016/0006-2944(77)90089-8.